Eikon Therapeutics IPO Priced at $18, Aims for $381M

IPO Pricing and Key Figures

Eikon Therapeutics, Inc. announced the pricing of its upsized initial public offering at $18.00 per share for 21,177,600 shares of common stock. The biopharmaceutical company anticipates gross proceeds of approximately $381 million before deductions for underwriting commissions and offering expenses.

Market Debut Details

The company's common stock is scheduled to debut on the Nasdaq Global Select Market on February 5, 2026, under the ticker symbol EIKN. The offering is anticipated to close around February 6, 2026, subject to customary closing conditions. Underwriters have been granted a 30-day option to purchase up to an additional 3,176,640 shares at the IPO price.

Company Profile and Capital Impact

Eikon is a late-stage clinical biopharmaceutical company focused on developing therapies for unmet medical needs, with an initial concentration in oncology. The capital raised from the IPO is expected to advance its drug candidates and support its proprietary single molecule tracking technology platform. The offering is managed by a syndicate including J.P. Morgan and Morgan Stanley as joint book-running managers.

Summary and Outlook

The successful pricing of this upsized IPO indicates significant investor interest in Eikon's clinical pipeline and technology. The market's reception of EIKN's debut will be a key event for the biopharmaceutical sector, reflecting broader sentiment towards clinical-stage companies seeking public funding.

FAQ

Q: What is Eikon Therapeutics' IPO price?
A: The initial public offering is priced at $18.00 per share.

Q: When will Eikon Therapeutics stock start trading?
A: The stock is scheduled to begin trading on the Nasdaq Global Select Market on February 5, 2026, under the ticker EIKN.

Source: Investing.com